GnRH agonist versus GnRH antagonist in assisted reproduction cycles: oocyte morphology

<p>Abstract</p> <p>Background</p> <p>The selection of developmentally competent human gametes may increase the efficiency of assisted reproduction. Spermatozoa and oocytes are usually assessed according to morphological criteria. Oocyte morphology can be affected by the...

Full description

Bibliographic Details
Main Authors: Cota Ana Marcia M, Oliveira Joao Batista A, Petersen Claudia G, Mauri Ana L, Massaro Fabiana C, Silva Liliane FI, Nicoletti Andreia, Cavagna Mario, Baruffi Ricardo LR, Franco José G
Format: Article
Language:English
Published: BMC 2012-04-01
Series:Reproductive Biology and Endocrinology
Subjects:
Online Access:http://www.rbej.com/content/10/1/33
_version_ 1828391237746425856
author Cota Ana Marcia M
Oliveira Joao Batista A
Petersen Claudia G
Mauri Ana L
Massaro Fabiana C
Silva Liliane FI
Nicoletti Andreia
Cavagna Mario
Baruffi Ricardo LR
Franco José G
author_facet Cota Ana Marcia M
Oliveira Joao Batista A
Petersen Claudia G
Mauri Ana L
Massaro Fabiana C
Silva Liliane FI
Nicoletti Andreia
Cavagna Mario
Baruffi Ricardo LR
Franco José G
author_sort Cota Ana Marcia M
collection DOAJ
description <p>Abstract</p> <p>Background</p> <p>The selection of developmentally competent human gametes may increase the efficiency of assisted reproduction. Spermatozoa and oocytes are usually assessed according to morphological criteria. Oocyte morphology can be affected by the age, genetic characteristics, and factors related to controlled ovarian stimulation. However, there is a lack of evidence in the literature concerning the effect of gonadotropin-releasing hormone (GnRH) analogues, either agonists or antagonists, on oocyte morphology. The aim of this randomized study was to investigate whether the prevalence of oocyte dysmorphism is influenced by the type of pituitary suppression used in ovarian stimulation.</p> <p>Methods</p> <p>A total of 64 patients in the first intracytoplasmic sperm injection (ICSI) cycle were prospectively randomized to receive treatment with either a GnRH agonist with a long-term protocol (n: 32) or a GnRH antagonist with a multi-dose protocol (n: 32). Before being subjected to ICSI, the oocytes at metaphase II from both groups were morphologically analyzed under an inverted light microscope at 400x magnification. The oocytes were classified as follows: normal or with cytoplasmic dysmorphism, extracytoplasmic dysmorphism, or both. The number of dysmorphic oocytes per total number of oocytes was analyzed.</p> <p>Results</p> <p>Out of a total of 681 oocytes, 189 (27.8 %) were morphologically normal, 220 (32.3 %) showed cytoplasmic dysmorphism, 124 (18.2%) showed extracytoplasmic alterations, and 148 (21.7%) exhibited both types of dysmorphism. No significant difference in oocyte dysmorphism was observed between the agonist- and antagonist-treated groups (<it>P</it> ≫ 0.05). Analysis for each dysmorphism revealed that the most common conditions were alterations in polar body shape (31.3%) and the presence of diffuse cytoplasmic granulations (22.8%), refractile bodies (18.5%) and central cytoplasmic granulations (13.6%). There was no significant difference among individual oocyte dysmorphisms in the agonist- and antagonist-treated groups (<it>P</it> ≫ 0.05).</p> <p>Conclusions</p> <p>Our randomized data indicate that in terms of the quality of oocyte morphology, there is no difference between the antagonist multi-dose protocol and the long-term agonist protocol. If a GnRH analogue used for pituitary suppression in IVF cycles influences the prevalence of oocyte dysmorphisms, there does not appear to be a difference between the use of an agonist as opposed to an antagonist.</p>
first_indexed 2024-12-10T06:58:15Z
format Article
id doaj.art-e80d64915b854066b9cf9e0b9ed6e5db
institution Directory Open Access Journal
issn 1477-7827
language English
last_indexed 2024-12-10T06:58:15Z
publishDate 2012-04-01
publisher BMC
record_format Article
series Reproductive Biology and Endocrinology
spelling doaj.art-e80d64915b854066b9cf9e0b9ed6e5db2022-12-22T01:58:23ZengBMCReproductive Biology and Endocrinology1477-78272012-04-011013310.1186/1477-7827-10-33GnRH agonist versus GnRH antagonist in assisted reproduction cycles: oocyte morphologyCota Ana Marcia MOliveira Joao Batista APetersen Claudia GMauri Ana LMassaro Fabiana CSilva Liliane FINicoletti AndreiaCavagna MarioBaruffi Ricardo LRFranco José G<p>Abstract</p> <p>Background</p> <p>The selection of developmentally competent human gametes may increase the efficiency of assisted reproduction. Spermatozoa and oocytes are usually assessed according to morphological criteria. Oocyte morphology can be affected by the age, genetic characteristics, and factors related to controlled ovarian stimulation. However, there is a lack of evidence in the literature concerning the effect of gonadotropin-releasing hormone (GnRH) analogues, either agonists or antagonists, on oocyte morphology. The aim of this randomized study was to investigate whether the prevalence of oocyte dysmorphism is influenced by the type of pituitary suppression used in ovarian stimulation.</p> <p>Methods</p> <p>A total of 64 patients in the first intracytoplasmic sperm injection (ICSI) cycle were prospectively randomized to receive treatment with either a GnRH agonist with a long-term protocol (n: 32) or a GnRH antagonist with a multi-dose protocol (n: 32). Before being subjected to ICSI, the oocytes at metaphase II from both groups were morphologically analyzed under an inverted light microscope at 400x magnification. The oocytes were classified as follows: normal or with cytoplasmic dysmorphism, extracytoplasmic dysmorphism, or both. The number of dysmorphic oocytes per total number of oocytes was analyzed.</p> <p>Results</p> <p>Out of a total of 681 oocytes, 189 (27.8 %) were morphologically normal, 220 (32.3 %) showed cytoplasmic dysmorphism, 124 (18.2%) showed extracytoplasmic alterations, and 148 (21.7%) exhibited both types of dysmorphism. No significant difference in oocyte dysmorphism was observed between the agonist- and antagonist-treated groups (<it>P</it> ≫ 0.05). Analysis for each dysmorphism revealed that the most common conditions were alterations in polar body shape (31.3%) and the presence of diffuse cytoplasmic granulations (22.8%), refractile bodies (18.5%) and central cytoplasmic granulations (13.6%). There was no significant difference among individual oocyte dysmorphisms in the agonist- and antagonist-treated groups (<it>P</it> ≫ 0.05).</p> <p>Conclusions</p> <p>Our randomized data indicate that in terms of the quality of oocyte morphology, there is no difference between the antagonist multi-dose protocol and the long-term agonist protocol. If a GnRH analogue used for pituitary suppression in IVF cycles influences the prevalence of oocyte dysmorphisms, there does not appear to be a difference between the use of an agonist as opposed to an antagonist.</p>http://www.rbej.com/content/10/1/33Oocyte morphology<it>in vitro</it> fertilizationGonadotropin-releasing hormone analoguesAssisted reproduction technique
spellingShingle Cota Ana Marcia M
Oliveira Joao Batista A
Petersen Claudia G
Mauri Ana L
Massaro Fabiana C
Silva Liliane FI
Nicoletti Andreia
Cavagna Mario
Baruffi Ricardo LR
Franco José G
GnRH agonist versus GnRH antagonist in assisted reproduction cycles: oocyte morphology
Reproductive Biology and Endocrinology
Oocyte morphology
<it>in vitro</it> fertilization
Gonadotropin-releasing hormone analogues
Assisted reproduction technique
title GnRH agonist versus GnRH antagonist in assisted reproduction cycles: oocyte morphology
title_full GnRH agonist versus GnRH antagonist in assisted reproduction cycles: oocyte morphology
title_fullStr GnRH agonist versus GnRH antagonist in assisted reproduction cycles: oocyte morphology
title_full_unstemmed GnRH agonist versus GnRH antagonist in assisted reproduction cycles: oocyte morphology
title_short GnRH agonist versus GnRH antagonist in assisted reproduction cycles: oocyte morphology
title_sort gnrh agonist versus gnrh antagonist in assisted reproduction cycles oocyte morphology
topic Oocyte morphology
<it>in vitro</it> fertilization
Gonadotropin-releasing hormone analogues
Assisted reproduction technique
url http://www.rbej.com/content/10/1/33
work_keys_str_mv AT cotaanamarciam gnrhagonistversusgnrhantagonistinassistedreproductioncyclesoocytemorphology
AT oliveirajoaobatistaa gnrhagonistversusgnrhantagonistinassistedreproductioncyclesoocytemorphology
AT petersenclaudiag gnrhagonistversusgnrhantagonistinassistedreproductioncyclesoocytemorphology
AT maurianal gnrhagonistversusgnrhantagonistinassistedreproductioncyclesoocytemorphology
AT massarofabianac gnrhagonistversusgnrhantagonistinassistedreproductioncyclesoocytemorphology
AT silvalilianefi gnrhagonistversusgnrhantagonistinassistedreproductioncyclesoocytemorphology
AT nicolettiandreia gnrhagonistversusgnrhantagonistinassistedreproductioncyclesoocytemorphology
AT cavagnamario gnrhagonistversusgnrhantagonistinassistedreproductioncyclesoocytemorphology
AT baruffiricardolr gnrhagonistversusgnrhantagonistinassistedreproductioncyclesoocytemorphology
AT francojoseg gnrhagonistversusgnrhantagonistinassistedreproductioncyclesoocytemorphology